Harvard Bioscience
(HBIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,899 | -1,052 | -1,401 | 2,355 | 2,374 |
| Depreciation Amortization | 3,360 | 2,278 | 1,178 | 3,939 | 2,835 |
| Income taxes - deferred | -1,024 | -1,027 | -255 | 1,412 | 259 |
| Accounts receivable | 754 | -2,136 | 115 | -735 | -557 |
| Accounts payable and accrued liabilities | 35 | 2,451 | 790 | 1,069 | 446 |
| Other Working Capital | -3,494 | -2,402 | -624 | -4,514 | -3,768 |
| Other Operating Activity | 1,209 | 907 | -300 | 825 | 1,499 |
| Operating Cash Flow | $-1,059 | $-981 | $-497 | $4,351 | $3,088 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,292 | -1,625 | -1,044 | -864 | -1,148 |
| Net Acquisitions | -4,545 | -4,545 | -4,545 | -12,653 | N/A |
| Investing Cash Flow | $-6,837 | $-6,170 | $-5,589 | $-13,517 | $-1,148 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 4,800 | 4,050 | 3,300 | 2,200 | 2,200 |
| Debt Repayment | -6,100 | -4,850 | -2,850 | -5,500 | -3,750 |
| Common Stock Issued | 1,953 | 1,864 | 382 | 2,066 | 1,415 |
| Other Financing Activity | -32 | -32 | 0 | 0 | 0 |
| Financing Cash Flow | $621 | $1,032 | $832 | $-1,234 | $-135 |
| Exchange Rate Effect | -769 | -613 | -849 | -1,237 | -842 |
| Beginning Cash Position | 14,134 | 14,134 | 14,134 | 25,771 | 25,771 |
| End Cash Position | 6,090 | 7,402 | 8,031 | 14,134 | 26,734 |
| Net Cash Flow | $-8,044 | $-6,732 | $-6,103 | $-11,637 | $963 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,059 | -981 | -497 | 4,351 | 3,088 |
| Capital Expenditure | -2,298 | -1,640 | -1,044 | -2,005 | -1,224 |
| Free Cash Flow | -3,357 | -2,621 | -1,541 | 2,346 | 1,864 |